



# Corrigendum: Longitudinal “Real-World” Outcomes of Pirfenidone in Idiopathic Pulmonary Fibrosis in Greece

## OPEN ACCESS

### Edited and Reviewed by:

Mehdi Mirsaeidi,  
University of Miami, United States

### \*Correspondence:

Argyrios Tzouvelekis  
argyrios.tzouvelekis@fleming.gr

<sup>†</sup>These authors have contributed  
equally to this work.

<sup>‡</sup>These authors jointly  
supervised the work.

### Specialty section:

This article was submitted to  
Pulmonary Medicine,  
a section of the journal  
Frontiers in Medicine

**Received:** 06 December 2017

**Accepted:** 22 December 2017

**Published:** 24 January 2018

### Citation:

Tzouvelekis A, Karampitsakos T,  
Ntolios P, Tzilas V, Bouros E,  
Markozannes E, Malliou I,  
Anagnostopoulos A, Granitsas A,  
Steiroopoulos P, Dimakou K,  
Chrysikos S, Koulouris N and  
Bouros D (2018) Corrigendum:  
Longitudinal “Real-World” Outcomes  
of Pirfenidone in Idiopathic Pulmonary  
Fibrosis in Greece.  
*Front. Med.* 4:257.  
doi: 10.3389/fmed.2017.00257

Argyrios Tzouvelekis<sup>1,2\*†‡</sup>, Theodoros Karampitsakos<sup>3†</sup>, Paschalis Ntolios<sup>4</sup>, Vasilios Tzilas<sup>1</sup>, Evangelos Bouros<sup>1</sup>, Evangelos Markozannes<sup>1</sup>, Ioanna Malliou<sup>1</sup>, Aris Anagnostopoulos<sup>1</sup>, Andreas Granitsas<sup>1</sup>, Paschalis Steiroopoulos<sup>2</sup>, Katerina Dimakou<sup>3</sup>, Serafeim Chrysikos<sup>4</sup>, Nikolaos Koulouris<sup>1</sup> and Demosthenes Bouros<sup>1†</sup>

<sup>1</sup>First Academic Department of Pneumology, Hospital for Diseases of the Chest “Sotiria”, Medical School, National and Kapodistrian University of Athens, Athens, Greece, <sup>2</sup>Division of Immunology, Biomedical Sciences Research Center “Alexander Fleming”, Athens, Greece, <sup>3</sup>5th Respiratory Department, Hospital for Diseases of the Chest “Sotiria”, Athens, Greece, <sup>4</sup>Department of Pneumology, University Hospital of Alexandroupolis, Democritus University of Thrace, Komotini, Greece

**Keywords:** pirfenidone, safety, efficacy, idiopathic pulmonary fibrosis, treatment

## A corrigendum on



### Longitudinal “Real-World” Outcomes of Pirfenidone in Idiopathic Pulmonary Fibrosis in Greece

by Tzouvelekis A, Karampitsakos T, Ntolios P, Tzilas V, Bouros E, Markozannes E, et al. *Front Med* (2017) 4:213. doi: 10.3389/fmed.2017.00213

In the original article, there was a mistake in **Figure 1** as published [*x* and *y* axes were mislabeled and \**p*-value <0.05 indicating significance was missing]. The corrected **Figure 1** appears below. The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way.

In the original article, there was a mistake in **Figure 2** as published [*x* and *y* axes were mislabeled and \**p*-value <0.05 indicating significance was missing]. The corrected **Figure 2** appears below. The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way.

The original article was updated.



**Conflict of Interest Statement:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2018 Tzouveleakis, Karampitsakos, Ntoliou, Tzilas, Bouros, Markozannes, Malliou, Anagnostopoulos, Granitsas, Steiropoulos, Dimakou, Chrysikos, Koulouris

and Bouros. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.